Comparing the current results to its competitors, Nexgel Inc reported Revenue increase in the 2 quarter 2026 by 63.24 % year on year. The sales growth was above Nexgel Inc 's competitors' average revenue growth of 2.86 %, achieved in the same quarter.
Nexgel Inc 's Comment on Competition and Industry Peers
NexGel is one of two manufacturers utilizing electron beam technology to produce high-performance hydrogels for wound care, cosmetic, and drug delivery applications. The other manufacturer does not currently offer products to the consumer market and therefore does not compete directly with NexGel. In the consumer products and medical device sectors, NexGel competes with various manufacturers, distributors, marketers, retailers, and physicians both in the United States and internationally. Notable competitors include Johnson & Johnson, Pfizer Consumer Healthcare, and Procter & Gamble. These competitors typically have longer operating histories, greater resources, more developed sales and distribution networks, stronger brand recognition, and larger established customer bases, making strategic partnerships important for NexGel's business development.
Sensus Healthcare Inc operates through a business model centered around the development, manufacturing, and marketing of advanced medical devices, primarily focused on providing non-invasive treatments for various skin conditions and cancers. The company aims to deliver effective and efficient solutions to healthcare providers, enabling them to deliver exceptional patient care and improve outcomes.
Avita Medical Inc is a medical technology company that specializes in regenerative medicine. Their business model focuses on developing and commercializing innovative products for the treatment of burns, chronic wounds, and other skin-related conditions.
Pulse Biosciences Inc's business model focuses on the development and commercialization of proprietary technology platforms, specifically in the field of nano-pulse stimulation (NPS) technology.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Nuo Therapeutics Inc's business model revolves around developing and commercializing innovative biologic therapies aimed at improving healthcare outcomes for patients. They focus on the research, development, and marketing of new therapeutic products, primarily in the wound care sector.
Sources:
Nexgel Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Nexgel Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
